Abstract
Background: Fibroblast growth factor-2 (FGF-2) has a role in the angiogenesis induced by renal carcinoma. Materials and Methods: Blockage of FGF-2 by an antisense oligonucleotide (ASO) or by a mouse neutralizing anti-human FGF-2 monoclonal antibody (anti-FGF-2-mAb) was evaluated on a cell line isolated from a renal carcinoma bone metastasis (CRBM-1990), on Caki-1 and ACHN cells. Cocultures of endothelial cells and ASO- or mAb-treated carcinoma lines were investigated. Results: Anti-FGF-2-mAb treatment induced a 33% reduction of FGF-2 released by ACHN, a 31% reduction of FGF-2 released by Caki-1, and a 70% reduction of FGF-2 released by CRBM-1990. ASO treatment did not inhibit endothelial cell proliferation. In contrast, anti-FGF-2-mAb significantly decreased endothelial cells proliferation induced by ACHN and CRBM-1990. The inhibition of endothelial cell growth was reverted by recombinant FGF-2. Conclusion: Modulation of FGF-2 production by renal cell carcinoma with a blocking mAb produced a significant inhibition of endothelial cell growth.
| Original language | English |
|---|---|
| Pages (from-to) | 315-320 |
| Number of pages | 6 |
| Journal | Anticancer Research |
| Volume | 27 |
| Issue number | 1 A |
| Publication status | Published - Jan 2007 |
Keywords
- Angiogenesis
- Antisense oligodeoxynucleotide
- Bone metastasis
- Fibroblast growth factor-2
- Neutralizing antibody
- Renal cell carcinoma
ASJC Scopus subject areas
- Cancer Research
- Oncology